704 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Liberty Square Wealth Partners LLC

Liberty Square Wealth Partners LLC acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 704 shares of the company's stock, valued at approximately $594,000.

A number of other hedge funds have also recently made changes to their positions in LLY. Great Valley Advisor Group Inc. lifted its stake in shares of Eli Lilly and Company by 7.2% in the 4th quarter. Great Valley Advisor Group Inc. now owns 24,756 shares of the company's stock valued at $19,111,000 after purchasing an additional 1,662 shares during the last quarter. Cypress Asset Management Inc. TX bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $17,269,000. Ameriflex Group Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $381,000. Sunbeam Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $1,407,000. Finally, Ascent Group LLC lifted its stake in shares of Eli Lilly and Company by 9.0% during the 4th quarter. Ascent Group LLC now owns 11,205 shares of the company's stock worth $8,650,000 after acquiring an additional 923 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price target for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research report on Friday. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

LLY traded up $11.03 on Tuesday, reaching $724.74. 3,786,668 shares of the stock were exchanged, compared to its average volume of 3,623,076. The company's 50-day moving average price is $786.82 and its 200 day moving average price is $802.40. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market capitalization of $686.86 billion, a PE ratio of 61.89, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the firm posted $2.58 EPS. The business's revenue was up 45.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.